Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Belzutifan
DRUG: Zanzalintinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]